Literature DB >> 15584992

Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000.

Cheolwon Suh1, Shin Kim, Sang-Hee Kim, Eun-Kyung Kim, Jae-Lyun Lee, Keon-Uk Park, Jung Sun Park, Jungsin Lee, Michael W Kim, Hyun-Sook Chi, Chan Jeong Park, Sang We Kim.   

Abstract

BACKGROUND: The most reliable index for timing peripheral blood progenitor cell (PBPC) collection following mobilization is still to be determined. The techniques to enumerate peripheral blood (PB) CD34+ cells are expensive and time-consuming. The SE9000 (Sysmex) provides an estimate of immature cells, called hematopoietic progenitor cells (HPCs). The aim of this study was to prospectively evaluate the efficacy of PB HPC levels for timing PBPC harvest. STUDY DESIGN AND METHODS: Thirty-five patients (15 non-Hodgkin's lymphoma and 20 multiple myeloma) were enrolled. PB HPCs and harvested CD34+ cells were counted with the SE9000 and flow cytometry, respectively. Circulating HPCs were monitored daily. PBPC harvest was initiated when HPC levels reached at least 5 per mm(3).
RESULTS: HPC levels reached 5 per mm(3) or more on Median Day 12 (range, days 9 to 16) of mobilizing chemotherapy. The median number of CD34+ cells collected per patient was 19.40 x 10(6) per kg (range, 1.94 x 10(6)-52.55 x 10(6) per kg). Both successful and optimal harvest was achieved in 97 percent of patients. PBPCs were successfully harvested in 25 patients (71%) in one session. An optimal harvest in a single session was attained in 16 patients (46%).
CONCLUSION: This might be the first prospective study showing the PB HPC level for timing PBPC harvest.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15584992     DOI: 10.1111/j.0041-1132.2004.04166.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Assessment of haematopoietic progenitor cell counting with the Sysmex® XN-1000 to guide timing of apheresis of peripheral blood stem cells.

Authors:  Francesco Dima; Erika Barison; Martina Midolo; Fabio Benedetti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2019-07-25       Impact factor: 3.443

2.  Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection.

Authors:  Se Na Lee; Ji Yeon Sohn; Jung Hee Kong; Hyeon Seok Eom; Hyewon Lee; Sun Young Kong
Journal:  Ann Lab Med       Date:  2017-07       Impact factor: 3.464

3.  Identification of cell morphology parameters from automatic hematology analyzers to predict the peripheral blood CD34-positive cell count after mobilization.

Authors:  Saeam Shin; Sung Ran Cho; Sinyoung Kim; Jong Rak Choi; Kyung-A Lee
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

4.  The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.

Authors:  So Yeon Jeon; Ho-Young Yhim; Hee Sun Kim; Jeong-A Kim; Deok-Hwan Yang; Jae-Yong Kwak
Journal:  Korean J Intern Med       Date:  2018-01-08       Impact factor: 2.884

5.  Algorithms utilizing peripheral blood hematopoietic progenitor cell counts in lieu of some CD34+ cell counts predict successful peripheral blood stem cell collections with substantial time and cost savings.

Authors:  B W Steussy; M Capper; M D Krasowski; N S Rosenthal; A J Schlueter
Journal:  ISBT Sci Ser       Date:  2016-10-05

6.  Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.

Authors:  Yong Pil Chong; Shin Kim; Ok Bae Ko; Ja Eun Koo; Danbi Lee; Sang Hyoung Park; Soo Jung Park; Daeho Lee; Sang We Kim; Cheolwon Suh
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.